Intec Pharma (NTEC) – Research Analysts’ Recent Ratings Changes

Intec Pharma (NASDAQ: NTEC) has recently received a number of price target changes and ratings updates:

  • 1/6/2018 – Intec Pharma was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $7.75 price target on the stock. According to Zacks, “Intec Pharma Ltd. is a biopharmaceutical company. The company focused on developing drugs through proprietary Accordion Pill platform technology. Its product candidates in clinical trial stages consists of Accordion Pill Carbidopa/Levodopa developed for the indication of treatment of Parkinson’s disease symptoms; Accordion Pill Zaleplon is being developed for the indication of treatment of insomnia, including sleep induction and the improvement of sleep maintenance. Intec Pharma Ltd. is based in JERUSALEM, Israel. “
  • 1/3/2018 – Intec Pharma was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Intec Pharma Ltd. is a biopharmaceutical company. The company focused on developing drugs through proprietary Accordion Pill platform technology. Its product candidates in clinical trial stages consists of Accordion Pill Carbidopa/Levodopa developed for the indication of treatment of Parkinson’s disease symptoms; Accordion Pill Zaleplon is being developed for the indication of treatment of insomnia, including sleep induction and the improvement of sleep maintenance. Intec Pharma Ltd. is based in JERUSALEM, Israel. “
  • 12/20/2017 – Intec Pharma was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $5.50 price target on the stock. According to Zacks, “Intec Pharma Ltd. is a biopharmaceutical company. The company focused on developing drugs through proprietary Accordion Pill platform technology. Its product candidates in clinical trial stages consists of Accordion Pill Carbidopa/Levodopa developed for the indication of treatment of Parkinson’s disease symptoms; Accordion Pill Zaleplon is being developed for the indication of treatment of insomnia, including sleep induction and the improvement of sleep maintenance. Intec Pharma Ltd. is based in JERUSALEM, Israel. “
  • 12/19/2017 – Intec Pharma was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Intec Pharma Ltd. is a biopharmaceutical company. The company focused on developing drugs through proprietary Accordion Pill platform technology. Its product candidates in clinical trial stages consists of Accordion Pill Carbidopa/Levodopa developed for the indication of treatment of Parkinson’s disease symptoms; Accordion Pill Zaleplon is being developed for the indication of treatment of insomnia, including sleep induction and the improvement of sleep maintenance. Intec Pharma Ltd. is based in JERUSALEM, Israel. “
  • 12/18/2017 – Intec Pharma was given a new $15.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.
  • 11/22/2017 – Intec Pharma was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $7.00 price target on the stock. According to Zacks, “Intec Pharma Ltd. is a biopharmaceutical company. The company focused on developing drugs through proprietary Accordion Pill platform technology. Its product candidates in clinical trial stages consists of Accordion Pill Carbidopa/Levodopa developed for the indication of treatment of Parkinson’s disease symptoms; Accordion Pill Zaleplon is being developed for the indication of treatment of insomnia, including sleep induction and the improvement of sleep maintenance. Intec Pharma Ltd. is based in JERUSALEM, Israel. “
  • 11/17/2017 – Intec Pharma was given a new $8.00 price target on by analysts at Maxim Group. They now have a “buy” rating on the stock. They wrote, “Intec reported 3Q17 with a net loss of $7.7M and ended the period with $63.0M in cash, including proceeds from a $57.5M equity financing. At the current burn rate, we estimate the company has runway into late 2019.””
  • 11/16/2017 – Intec Pharma was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 11/16/2017 – Intec Pharma was given a new $15.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.

Intec Pharma Ltd (NASDAQ NTEC) opened at $7.00 on Tuesday. Intec Pharma Ltd has a fifty-two week low of $4.20 and a fifty-two week high of $9.80.

Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.

Receive News & Ratings for Intec Pharma Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma Ltd and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit